Recently, the China National Intellectual Property Administration issued its Decision on the Awarding of the 24th China Patent Award. The invention patent "EGFR Inhibitor and Preparation and Application Thereof" (Patent No.: ZL 201580045311.2) for the innovative drug Ameile (Aumolertinib Mesylate Tablets) developed by Hansoh Pharma, won the 24th China Patent Gold Award. This follows the honor that Hansoh Pharma received for the Zefei (Gemcitabine Hydrochloride for Injection) patent for which it won the China Patent Gold Award. The China Patent Gold Award is the highest level honor that can be received in China for granted patents. Winning it twice signifies that the innovation engine continuously built by Hansoh Pharma has unleashed tremendous momentum, driving the company into the fast track of innovative development. As of now, the company has marketed seven innovative drugs, and has more than 30 innovative drug programs in different clinical stages with over 40 clinical trials in progress, The R&D scope covers cutting-edge international technology areas such as monoclonal antibodies, bispecific antibodies, siRNA, ADC, and fusion proteins.  The successful outcomes of R&D innovation can be attributed to Hansoh Pharma's forward-thinking patent layout, systematic institutional construction, and intensive resource investment. The patent affairs team at Hansoh Pharma has formulated and implemented over 20 intellectual property management systems. They have built a comprehensive, multi-level patent layout that encompasses compounds, pharmaceutical crystal forms, pharmaceutical formulation, intermediates, preparation processes, and medical uses, providing comprehensive and three-dimensional patent protection which has enabled the company to maintain its competitive position for products in both Chinese and international markets. Hansoh Pharma has won two China Patent Gold Awards, one Silver Award, six Excellence Awards, and one Jiangsu Province Patent Gold Award. The company has been recognized as a National Intellectual Property Model Enterprise by the National Intellectual Property Administration for many consecutive years. The High-value Patent Cultivation Demonstration Center project led by Hansoh Pharma was promoted as a model case nationwide by the National Intellectual Property Administration in 2021. As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma will continue to enhance its intellectual property management level and accelerate the pace of scientific and technological innovation, with the purpose of meeting the clinical needs of patients in China and globally. The company is committed to exploring and developing more innovative and effective drugs in order to improve the quality of human life.